{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T09:46:30Z","timestamp":1781084790206,"version":"3.54.1"},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,1,1]]},"DOI":"10.2169\/internalmedicine.3315-19","type":"journal-article","created":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T17:04:13Z","timestamp":1577811853000},"page":"93-99","source":"Crossref","is-referenced-by-count":5,"title":["Eculizumab for Severe Thrombotic Microangiopathy Secondary to Surgical Invasive Stress and Bleeding"],"prefix":"10.2169","volume":"59","author":[{"given":"Yoko","family":"Fujita","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maho","family":"Terashita","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Yazawa","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukitaka","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, St. Marianna University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Imamura","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Tokyo Metropolitan Police Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro","family":"Kibayashi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Yokohama General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Sawai","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Shiga University of Medical Science, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Hidaka","sequence":"additional","affiliation":[{"name":"Department of Molecular Genetics, Wakayama Medical University, Japan"},{"name":"The Japanese Association for Complement Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuki","family":"Ohtani","sequence":"additional","affiliation":[{"name":"The Japanese Association for Complement Research, Japan"},{"name":"Department of Food and Health Sciences, Rakuno Gakuen University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimitsu","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Molecular Genetics, Wakayama Medical University, Japan"},{"name":"The Japanese Association for Complement Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugo","family":"Shibagaki","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 361: 1676-1687, 2009.","DOI":"10.1056\/NEJMra0902814"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 371: 654-666, 2014.","DOI":"10.1056\/NEJMra1312353"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5: 1844-1859, 2010.","DOI":"10.2215\/CJN.02210310"},{"key":"4","unstructured":"4. Asif A, Nayer A, Haas CS. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. J Nephrol 30: 347-362, 2017."},{"key":"5","unstructured":"5. Riedl M, Fakhouri F, Le Quintrec M, et al. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost 40: 444-464, 2014."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Berger BE. The alternative pathway of complement and the evolving clinical-pathophysiological spectrum of atypical hemolytic uremic syndrome. Am J Med Sci 352: 177-190, 2016.","DOI":"10.1016\/j.amjms.2016.05.003"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368: 2169-2181, 2013.","DOI":"10.1056\/NEJMoa1208981"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Nester CM, Thomas CP. Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? Hematology American Society of Hematology Education Program 2012: 617-625, 2012.","DOI":"10.1182\/asheducation.V2012.1.617.3798924"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kransdorf EP, Kittleson MM, Kobashigawa JA. Atypical hemolytic-uremic syndrome immediately after heart transplantation. J Heart Lung Transplant 33: 664-665, 2014.","DOI":"10.1016\/j.healun.2014.02.006"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Azoulay E, Knoebl P, Garnacho-Montero J, et al. Expert statements on the standard of care in critically ill adult patients with atypical hemolytic uremic syndrome. Chest 152: 424-434, 2017.","DOI":"10.1016\/j.chest.2017.03.055"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Afshar-Kharghan V. Atypical hemolytic uremic syndrome. Hematology American Society of Hematology Education Program 2016: 217-225, 2016.","DOI":"10.1182\/asheducation-2016.1.217"},{"key":"12","unstructured":"12. Matsumoto T, Fan X, Ishikawa E, et al. Analysis of patients with atypical hemolytic uremic syndrome treated at the Mie University Hospital: concentration of C3 p.I1157T mutation. Int J Hematol 100: 437-442, 2014."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Rinder CS, Rinder HM, Smith BR, et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 96: 1564-1572, 1995.","DOI":"10.1172\/JCI118195"},{"key":"14","unstructured":"14. Heesterbeek DAC, Angelier ML, Harrison RA, Rooijakkers SHM. Complement and bacterial infections: from molecular mechanisms to therapeutic applications. J Innate Immun 10: 455-464, 2018."},{"key":"15","unstructured":"15. Winthrop KL, Mariette X, Silva JT, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 24 (Suppl 2): S21-S40, 2018."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Marshall JM, Gunn JS. The O-antigen capsule of Salmonella enterica serovar typhimurium facilitates serum resistance and surface expression of FliC. Infect Immun 83: 3946-3959, 2015.","DOI":"10.1128\/IAI.00634-15"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Huerta A, Arjona E, Portoles J, et al. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. Kidney Int 93: 450-459, 2018.","DOI":"10.1016\/j.kint.2017.06.022"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Macia M, de Alvaro Moreno F, Dutt T, et al. Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome. Clin Kidney J 10: 310-319, 2017.","DOI":"10.1093\/ckj\/sfw115"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/1\/59_3315-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T00:35:27Z","timestamp":1578270927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/1\/59_3315-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3315-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,1]]}}}